MicroRNAs and depression

Neurobiology of Disease

Volumn 46, Issue 2, 2012, Pages 272-278

  Mouillet Richard, Sophie ^a,b   Baudry, Anne ^a,b   Launay, Jean Marie ^c,d   Kellermann, Odile ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Antidepressant; Depression; MicroRNA

Indexed keywords

LITHIUM; MICRORNA; MICRORNA 16; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; VALPROIC ACID;

5 HTTPLR GENE; BDNF GENE; CIRCADIAN RHYTHM; DEPRESSION; DRUG MECHANISM; DRUG TARGETING; EPIGENETICS; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HOMER1 GENE; HUMAN; MARKER GENE; MENTAL STRESS; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROPATHOLOGY; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SLC6A15 GENE; SLC6A4 GENE;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICRORNAS;

EID: 84859502170     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.12.035     Document Type: Review

References (102)

1. Allen N.J., Barres B.A. Neuroscience: glia - more than just brain glue. Nature 2009, 457:675-677.
2. Alvarez-Saavedra M., et al. miRNA-132 orchestrates chromatin remodeling and translational control of the circadian clock. Hum. Mol. Genet. 2011, 20:731-751.
3. Anacker C., et al. The glucocorticoid receptor: pivot of depression and of antidepressant treatment?. Psychoneuroendocrinology 2011, 36:415-425.
4. Aqeilan R.I., et al. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ. 2010, 17:215-220.
5. Baffa A., et al. Norepinephrine and serotonin transporter genes: impact on treatment response in depression. Neuropsychobiology 2010, 62:121-131.
6. Baudry A., et al. New views on antidepressant action. Curr. Opin. Neurobiol. 2011, 21:1-8.
7. Baudry A., et al. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 2010, 329:1537-1541.
8. Beaulieu J.M., Caron M.G. Looking at lithium: molecular moods and complex behaviour. Mol. Interv. 2008, 8:230-241.
9. Benmansour S., et al. Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J. Neurosci. 2002, 22:6766-6772.
10. Benton C., Wiltshire T. Biological alterations in depression. Psychiatric disorders - trends and development. Tech 2011, 223-266.
11. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci. 2006, 7:137-151.
12. Blume J., et al. Immune suppression and immune activation in depression. Brain Behav. Immun. 2011, 25:221-229.
13. Bosker F.J., et al. Poor replication of candidate genes for major depressive disorder using genome-wide association data. Mol. Psychiatry 2011, 16:516-532.
14. Cao J.L., et al. Mesolimbic dopamine neurons in the brain reward circuit mediate susceptibility to social defeat and antidepressant action. J. Neurosci. 2010, 30:16453-16458.
15. Cao R., Obrietan K. mTOR signaling and entrainment of the mammalian circadian clock. Mol. Cell. Pharmacol. 2010, 2:125-130.
16. Caspi A., et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386-389.
17. Castren E., Rantamaki T. The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev. Neurobiol. 2010, 70:289-297.
18. Chahrour M., et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 2008, 320:1224-1229.
19. Cheng H.Y., Obrietan K. Revealing a role of microRNAs in the regulation of the biological clock. Cell Cycle 2007, 6:3034-3035.
20. Cheng L.C., et al. miR-124 regulates adult neurogenesis in the subventricular zone stem cell niche. Nat. Neurosci. 2009, 12:399-408.
21. Coppen A. The biochemistry of affective disorders. Br. J. Psychiatry 1967, 113:1237-1264.
22. Covington H.E., et al. From synapse to nucleus: novel targets for treating depression. Neuropharmacology 2010, 58:683-693.
23. Cryan J.F., O'Leary O.F. Neuroscience. A glutamate pathway to faster-acting antidepressants?. Science 2010, 329:913-914.
24. Diaz de Leon-Guerrero S., et al. In sickness and in health: the role of methyl-CpG binding protein 2 in the central nervous system. Eur. J. Neurosci. 2011, 33:1563-1574.
25. Dudley K.J., et al. Epigenetic mechanisms mediating vulnerability and resilience to psychiatric disorders. Neurosci. Biobehav. Rev. 2011, 35:1544-1551.
26. Duman R.S. Depression: a case of neuronal life and death?. Biol. Psychiatry 2004, 56:140-145.
27. Dwivedi Y. Evidence demonstrating role of microRNAs in the etiopathology of major depression. J. Chem. Neuroanat. 2011, 42:142-156.
28. Ebmeier K.P., et al. Recent developments and current controversies in depression. Lancet 2006, 367:153-167.
29. Feder A., et al. Psychobiology and molecular genetics of resilience. Nat. Rev. Neurosci. 2009, 10:446-457.
30. Fiori, L. M., Turecki, G., 2012. Broadening our horizons: Gene expression profiling to help better understand the neurobiology of suicide and depression. Neurobiol. Dis. 45, 14-22.
31. Gao J., et al. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature 2010, 466:1105-1109.
32. Garzon R., et al. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 2010, 9:775-789.
33. Greer P.L., Greenberg M.E. From synapse to nucleus: calcium-dependent gene transcription in the control of synapse development and function. Neuron 2008, 59:846-860.
34. Haenisch B., Bonisch H. Depression and antidepressants: insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters. Pharmacol. Ther. 2011, 129:352-368.
35. Hanson N.D., et al. Depression, antidepressants, and neurogenesis: a critical reappraisal. Neuropsychopharmacology 2011, 36:2589-2602.
36. Hashimoto K. The role of glutamate on the action of antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 35:1158-1168.
37. Hercher C., et al. Through the looking glass: examining neuroanatomical evidence for cellular alterations in major depression. J. Psychiatr. Res. 2009, 43:947-961.
38. Holsboer F., Ising M. Stress hormone regulation: biological role and translation into therapy. Annu. Rev. Psychol. 2010, 61(81-109):C1-C11.
39. Hsieh J., Eisch A.J. Epigenetics, hippocampal neurogenesis, and neuropsychiatric disorders: unraveling the genome to understand the mind. Neurobiol. Dis. 2010, 39:73-84.
40. Iorio M.V., et al. Interplay between microRNAs and the epigenetic machinery: an intricate network. Biochim. Biophys. Acta 2010, 1799:694-701.
41. Jensen K.P., et al. A common polymorphism in serotonin receptor 1B mRNA moderates regulation by miR-96 and associates with aggressive human behaviors. Mol. Psychiatry 2009, 14:381-389.
42. Kawashima H., et al. Glucocorticoid attenuates brain-derived neurotrophic factor-dependent upregulation of glutamate receptors via the suppression of microRNA-132 expression. Neuroscience 2010, 165:1301-1311.
43. Klein M.E., et al. Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. Nat. Neurosci. 2007, 10:1513-1514.
44. Kohli M.A., et al. The neuronal transporter gene SLC6A15 confers risk to major depression. Neuron 2011, 70:252-265.
45. Krishnan V., Nestler E.J. Linking molecules to mood: new insight into the biology of depression. Am. J. Psychiatry 2010, 167:1305-1320.
46. Krol J., et al. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 2010, 11:597-610.
47. Lagos-Quintana M., et al. Identification of tissue-specific microRNAs from mouse. Curr. Biol. 2002, 12:735-739.
48. Lapin I.P., Oxenkrug G.F. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1969, 1:132-136.
49. Launay, J. M., et al., 2011. Raphe-mediated signals control the hippocampal response to SRI antidepressants via miR-16. Transl. Psychiatry. 1 e56.
50. Lee S., et al. Depression research: where are we now?. Mol. Brain 2010, 3:8.
51. Lesch K.P. When the serotonin transporter gene meets adversity: the contribution of animal models to understanding epigenetic mechanisms in affective disorders and resilience. Curr. Top. Behav. Neurosci. 2011, 7:251-280.
52. Levinson D.F. The genetics of depression: a review. Biol. Psychiatry 2006, 60:84-92.
53. Li N., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
54. Li N., et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 2011, 69:754-761.
55. Luikart, B. W., et al., in press. Dentate gyrus neurogenesis, integration and microRNAs. Behav. Brain Res.
56. Luscher B., et al. The GABAergic deficit hypothesis of major depressive disorder. Mol. Psychiatry 2010, 16:383-406.
57. Ma D.K., et al. Epigenetic choreographers of neurogenesis in the adult mammalian brain. Nat. Neurosci. 2010, 13:1338-1344.
58. Macqueen G., Frodl T. The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research?. Mol. Psychiatry 2010, 16:252-264.
59. Magill S.T., et al. MicroRNA-132 regulates dendritic growth and arborization of newborn neurons in the adult hippocampus. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:20382-20387.
60. Meerson A., et al. Changes in brain microRNAs contribute to cholinergic stress reactions. J. Mol. Neurosci. 2010, 40:47-55.
61. Mendlewicz J. Disruption of the circadian timing systems: molecular mechanisms in mood disorders. CNS Drugs 2009, 23(Suppl. 2):15-26.
62. Millan M.J. MicroRNA in the regulation and expression of serotonergic transmission in the brain and other tissues. Curr. Opin. Pharmacol. 2011, 11:11-22.
63. Mitchell N.D., Baker G.B. An update on the role of glutamate in the pathophysiology of depression. Acta Psychiatr. Scand. 2010, 122:192-210.
64. Monteleone P., et al. Circadian rhythms and treatment implications in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 35:1569-1574.
65. Murphy D.L., Lesch K.P. Targeting the murine serotonin transporter: insights into human neurobiology. Nat. Rev. Neurosci. 2008, 9:85-96.
66. Murphy D.L., Moya P.R. Human serotonin transporter gene (SLC6A4) variants: their contributions to understanding pharmacogenomic and other functional GxG and GxE differences in health and disease. Curr. Opin. Pharmacol. 2011, 11:3-10.
67. Nestler E.J., Hyman S.E. Animal models of neuropsychiatric disorders. Nat. Neurosci. 2010, 13:1161-1169.
68. Nierenberg A.A., et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J. Clin. Psychiatry 1999, 60:221-225.
69. Peterson B.S., Weissman M.M. A brain-based endophenotype for major depressive disorder. Annu. Rev. Med. 2011, 62:461-474.
70. Pinsonneault J.K., et al. Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder. Neuropsychopharmacology 2011, 36:1644-1655.
71. Pittenger C., Duman R.S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008, 33:88-109.
72. Rajasethupathy P., et al. Characterization of small RNAs in Aplysia reveals a role for miR-124 in constraining synaptic plasticity through CREB. Neuron 2009, 63:803-817.
73. Rajewsky N. MicroRNAs and the Operon paper. J. Mol. Biol. 2011, 409:70-75.
74. Rietschel M., et al. Genome-wide association-, replication-, and neuroimaging study implicates HOMER1 in the etiology of major depression. Biol. Psychiatry 2010, 68:578-585.
75. Rinaldi A., et al. Stress induces region specific alterations in microRNAs expression in mice. Behav. Brain Res. 2010, 208:265-269.
76. Rush A.J., et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med. 2006, 354:1231-1242.
77. Ryan B.M., et al. Genetic variation in microRNA networks: the implications for cancer research. Nat. Rev. Cancer 2010, 10:389-402.
78. Saus E., et al. Genetic variants and abnormal processing of pre-miR-182, a circadian clock modulator, in major depression patients with late insomnia. Hum. Mol. Genet. 2010, 19:4017-4025.
79. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry 1965, 122:509-522.
80. Schratt G. MicroRNAs at the synapse. Nat. Rev. Neurosci. 2009, 10:842-849.
81. Schratt G.M., et al. BDNF regulates the translation of a select group of mRNAs by a mammalian target of rapamycin-phosphatidylinositol 3-kinase-dependent pathway during neuronal development. J. Neurosci. 2004, 24:7366-7377.
82. Schratt G.M., et al. A brain-specific microRNA regulates dendritic spine development. Nature 2006, 439:283-289.
83. Sethupathy P., Collins F.S. MicroRNA target site polymorphisms and human disease. Trends Genet. 2008, 24:489-497.
84. Shi Y., et al. MicroRNA regulation of neural stem cells and neurogenesis. J. Neurosci. 2010, 30:14931-14936.
85. Shirayama Y., Chaki S. Neurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodents. Curr. Neuropharmacol. 2006, 4:277-291.
86. Siegel G., et al. MicroRNAs in neurons: manifold regulatory roles at the synapse. Curr. Opin. Genet. Dev. 2011, 21:491-497.
87. Sun G., et al. SNPs in human miRNA genes affect biogenesis and function. RNA 2009, 15:1640-1651.
88. Surget A., et al. Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal. Neuropsychopharmacology 2009, 34:1363-1380.
89. Talbot J.N., et al. RGS inhibition at G(alpha)i2 selectively potentiates 5-HT1A-mediated antidepressant effects. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:11086-11091.
90. Tang X., et al. Glycogen synthase kinase 3 beta (GSK3beta) phosphorylates the RNAase III enzyme drosha at S300 and S302. PLoS One 2011, 6:e20391.
91. Tanti A., Belzung C. Open questions in current models of antidepressant action. Br. J. Pharmacol. 2010, 159:1187-1200.
92. Trivedi M.H., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 2006, 163:28-40.
93. Tsankova N.M., et al. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat. Neurosci. 2006, 9:519-525.
94. Uchida S., et al. Early life stress enhances behavioral vulnerability to stress through the activation of REST4-mediated gene transcription in the medial prefrontal cortex of rodents. J. Neurosci. 2010, 30:15007-15018.
95. Uchida S., et al. Epigenetic status of Gdnf in the ventral striatum determines susceptibility and adaptation to daily stressful events. Neuron 2011, 69:359-372.
96. Vo N., et al. A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:16426-16431.
97. Wada A. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades. J. Pharmacol. Sci. 2009, 110:14-28.
98. Wang J.W., et al. The when and where of BDNF and the antidepressant response. Biol. Psychiatry 2008, 63:640-641.
99. Xu Y., et al. A polymorphism in the microRNA-30e precursor associated with major depressive disorder risk and P300 waveform. J. Affect. Disord. 2010, 127:332-336.
100. Younger S.T., Corey D.R. Transcriptional gene silencing in mammalian cells by miRNA mimics that target gene promoters. Nucleic Acids Res. 2011, 39:5682-5691.
101. Zhao Z., et al. Association of changes in norepinephrine and serotonin transporter expression with the long-term behavioral effects of antidepressant drugs. Neuropsychopharmacology 2009, 34:1467-1481.
102. Zhou R., et al. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 2009, 34:1395-1405.